Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis

PARIS, Nov. 28, 2021 /PRNewswire/ -- Therapixel, a company leading the use of AI-based products for women's health, announces it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MammoScreen®, the explainable and actionable Artificial Intelligence...

from PR Newswire: https://ift.tt/3p1BoZg